SCM
KYNB

Soleus Capital Management’s Kyntra Bio KYNB Stock Holding History

Soleus Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,179
Closed -$2.42M – 103
2023
Q1 		$2.42M Buy
5,179
+640
+14% +$339K 0.25% 62
2022
Q4 		$1.82M Sell
4,539
-4,822
-52% -$1.85M 0.26% 62
2022
Q3 		$3.04M Sell
9,361
-2,728
-23% -$879K 0.41% 52
2022
Q2 		$3.19M Sell
12,089
-30,485
-72% -$7.79M 0.5% 54
2022
Q1 		$12.8M Sell
42,574
-19,446
-31% -$6.78M 1.65% 22
2021
Q4 		$21.9M Buy
+62,020
New +$19.3M 2.19% 12

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's KYNB Position: Q2 2023 in Review

Soleus Capital Management sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 5,179 shares — an estimated $2.42M sold.

Soleus Capital Management first reported a position in KYNB in Q4 2021 and held it in 6 quarters. The position peaked at $21.9M in Q4 2021. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Soleus Capital Management reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Soleus Capital Management sold 5,179 Kyntra Bio shares in Q2 2023, an estimated $2.42M.
  • Soleus Capital Management first reported a position in Kyntra Bio in Q4 2021 and held it in 6 quarters.
  • Soleus Capital Management's Kyntra Bio position peaked at $21.9M in Q4 2021.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.